NeuroSense Therapeutics Ltd. (NRSN)
NeuroSense Therapeutics develops drug candidates for neurodegenerative diseases, led by PrimeC for ALS. It last closed at $1.53 on Nov 17, down 3.77% on the day. NRSN last reported earnings on Tue, Jun 30, 2026.
Key Stats
Last 12 monthsNot reported for this period.
From NRSN's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 31). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on NRSN in the past 90 days. The average target is $52.00, with a high of $52.00 and a low of $52.00, compared with the last close of $1.53.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 28 | HC Wainwright & Co. | Target raised | Buy | $8 → $52 |
| Sep 3 | HC Wainwright & Co. | Initiated | Buy | $8 |
Technical Analysis
The stock is 25% below its 20 day and 150% below its 50 day average. It is 673% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the Pivot S1 at $1.50, and the nearest resistance the Pivot R1 at $1.56.
| RSI (14) | 28.68 | Oversold below 30 | Oversold |
| MACD | -0.62 | Above its signal line | Bullish |
| Stochastic | 29.7 | Middle of its range | Neutral |
| ADX (14) | 45.4 | Strong downtrend | |
| Williams %R | -75.2 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -74.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +15.5% | Change over 10 sessions | Bullish |
| ATR (14) | $0.34 | Typical daily range, 22.3% of price |
| RSI (14) | 25.03 | Oversold below 30 | Oversold |
| MACD | -3.57 | Below its signal line | Bearish |
| Stochastic | 3.9 | Near the bottom of its range | Oversold |
| ADX (14) | 30.5 | Trending down | |
| Williams %R | -97.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -105.0 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −78.0% | Change over 10 sessions | Bearish |
| ATR (14) | $2.05 | Typical daily range, 134.1% of price |
What happened before
See how NRSN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NRSN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in NRSN in the last 90 days.
NRSN Institutional Ownership
Full report →- ▼5 buying vs 12 selling
- ▼Shares held by funds -99.3%
- ▼Funds holding -7
- ●No superinvestor moves
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 5 | 12 | −58.3% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | – | – | – |
| New / increased | 5 / 0 | 2 / 2 | +25.0% |
| Reduced / sold out | 0 / 12 | 2 / 3 | +140.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NRSN is in one of them and how their past NRSN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NRSN in an article yet. Here's the latest on the wider market.
NRSN Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Lee ZeldinExecutive branch | Buy | $1K – $15K | Aug 1, 2025 | Nov 18, 2025 | 109 d |
| Lee ZeldinExecutive branch | Sell | $1K – $15K | May 13, 2025 | Jul 15, 2025 | 63 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About NeuroSense Therapeutics
NeuroSense Therapeutics is a biotechnology company based in Herzliya, Israel, that develops treatments for neurodegenerative diseases such as ALS, Alzheimer's disease and Parkinson's disease. Its lead candidate, PrimeC, is an oral combination of two drugs already approved by the FDA, ciprofloxacin and celecoxib, and it is being developed for people living with ALS. The company is seeking regulatory approval for PrimeC, and its intended users are patients and the healthcare systems that treat them.
- Headquarters
- Herzliya, Israel
